Jennerex raises $5M to treat cancer-related viruses

Jennerex, a long-time developer of therapeutics for cancer patients, has branched into treatments targeting oncolytic viruses — viruses that specifically infect cancer cells — and it just raised $5.1 million in third-round funding to fuel its efforts. Based in San Francisco, the company has kept the round open, hoping to raise more before it closes next month. It previously raised an $8.3 million second round last fall, reports PE Hub. It has not disclosed the identity of its investors.

Jennerex plans to use its new financing to continue pushing its lead product through clinical trials. It is currently in phase three trials for liver cancer, phase two trials for colon cancer and its first set of trials for lung cancer.

Next Story: Entrepreneur Corner roundup: Marketing priorities, angel investor secrets and more
Previous Story: Crescendo captures $5M to accelerate delivery of web apps